2017 Results

2017 product strategy: investments and first results

Sales up 8%: €12,165,000

Net profit up 11.6%: €566,000

 

Lyon, May 2, 2018

SBT achieved a steady increase in its consolidated sales (+8%), reaching €12,165,000 (or +€893,000 compared to 2016). Against a backdrop of strong investments to build an expanded product offer, profitability remains at the same level as last year with a net profit after taxes of €566,000, or 4.6% of sales. EBITDA represents 10% of sales. The workforce grew significantly by 18% (or 84 employees as of December 31, 2017) to ensure the 2020 growth plan.

A single acquisition, which had little impact on the consolidated financial statement, was completed in 2016 (Twincorp). Sales growth is thus largely organic, demonstrating the relevance of the model implemented by management.

Consolidated sales (€K) 2017 2016 Variation in €K
Sales 12,165 11,272 + 893
EBITDA 1,237 1,221 + 16
Net profit from consolidated companies 566 506 + 60

 

On December 31, 2017, the SBT group had a solid balance sheet structure with growing shareholder equity amounting to €6,256,000 (+€542,000), financial debts of €874,000 (+€429,000) in connection with the acquisition of Twincorp and the relocation of the Lyon and Paris sites, and a cash holding of €856,000 (-€568,000).

 

Increased integration of the Consulting & HR Division

SBT offers enriched services integrating the various activities of the group’s subsidiaries (strategic consulting, assessment, development, coaching). Eliminating internal billing, the Consulting and HR Division contributed €9.5 million, closing the financial year with an increase of €539,000 (+6.7%).

Major highlights included integrating the coaching activity into the offer and gradually accelerating the Learn activity.

 

Continued growth for the Health Division

The Health Division contributed €2.6 million to consolidated sales in 2017, an increase of nearly 18%, while maintaining a profitability of approximately 10%, or €255,000.

HappyNeuron stands out as the Francophone market leader for cognitive remediation platforms designed for healthcare professionals. Significant investments were made beginning in 2017 with the aim of extending this position internationally, particularly in the North American market, in order to take advantage of the excellent references already obtained by the platform.

 

/par

2016 Results

2016, SBT continues to grow

Sales up by 10.7%: €11.3 million

Stable net income +1.6%: €506,000

 

SBT (FR0004175222, MLSBT) is a group specializing in consulting and development of innovative services that integrate new technologies, cognitive engineering, and neuroscience.

In 2016, SBT saw continued growth in its consolidated turnover (+10.7%), which reached €11,272,000 (or +€1,088,000 compared to 2015). In a context of investments (increased resources and staffing), profitability remains satisfactory with a net profit of €506,000 after taxes, or 4.5% of turnover.

As no acquisitions were made in 2016, growth in sales is entirely organic, demonstrating the relevance of the model implemented by management.

Consolidated sales (€K) 2016 2015 Variation in €K
Sales 11,272 10,184 + 1,088
EBITDA 1,221 847 + 374
Net income of consolidated companies 506 497 + 9

 

On December 31, 2016, the SBT Group had a solid balance sheet structure with shareholder equity amounting to €5,714,000 (+€537,000), financial debts decreasing to €445,000 (-€213,000) and €1,414,000 in cash holdings (+139,000€).

 

The Consulting and HR Division internationalizes

All of the division’s activities reported growth in sales. Arnava recorded strong growth (+24%), reaping the rewards of a strategic reorientation. OSE Consulting experienced steady growth (+8%), and Symétrix grew moderately (1.3%) due to management and team restructuring carried out throughout the year. The Consulting & HR division generated €8.9 million in sales for a net profit of €423,000 (including a €290,000 SBT SA debt cancellation for Symétrix, which was granted to facilitate restructuring).

The main highlights included the opening of two subsidiaries: one in New York and the other in Hong Kong to support large accounts, open new markets, and continue digitalizing the HR consulting business (assessment, coaching, development, etc.).

 

The Health Division solidifies growth.

 

The expected commercial synergies resulting from the acquisition of Motus’ business assets are taking root and speeding up growth. The Health Division increased turnover by nearly 30% in 2016 to €2.2 million while maintaining the same 14% profitability for a total of €274,000.

 

In particular, HappyNeuron once again increased its penetration rate among healthcare professionals by relying on a service offer recently strengthened by the arrival of a new platform integrating its activities and allowing professionals to manage their patient programs.

 

/par

The SBT Group acquires the TWIN CORP, the international coaching platform.

SBT, Scientific Brain Training, (FR0004175222, MLSBT), a group specializing in consulting and development of innovative services that integrate new technologies, cognitive engineering, and neuroscience, announces that, as of Monday, January 30, 2017, they have concluded the acquisition of the start-up TWIN CORP, the only international remote coaching platform for leaders, managers and business experts.

The coaching market is booming in France and internationally thanks to several strengths:

  • Individual coaching increases the effectiveness of employees in companies.
  • Employees expect a more individualized approach, adapted to their context, agenda, and centered around their needs.
  • Companies are faced with a paradox: industrializing individualized employee development while managing constraints: budget, centralized global management, time saving, organizational simplicity, etc.

TWIN CORP brings innovative and agile coaching solutions to the market without departing from the ethics and high standards used by the best coaches.  TWIN CORP offers:

  • The first digital remote coaching solution to develop employee efficiency in all areas.
  • A minimum of 3 hours of coaching to successfully manage transformation projects, skill development programs, and individual situations.
  • The guaranteed involvement of experienced international coaches and support for companies in the development and implementation of their projects.
  • A smartphone application and web platform for choosing a coach and booking sessions on demand.
  • Resources: 28 coaches in Asia, the US, South America, and Europe recruited according to stringent criteria.

With over two years of positive customer experience, TWIN CORP stands out with large international groups as THE facilitating, expert solution when it comes to coaching and professional development, with a projected turnover of approximately 600,000 EUROS in 2017.

For SBT’s Chairman, Olivier Fronty:  “The acquisition of TWIN CORP allows us to offer an innovative tool that complements the Group’s HR approach by strengthening the individual approach. It provides further proof of the Group’s desire to create new labels. It also allows us to integrate all of our cognitive science knowledge into these digital approaches.”

For Perrine Dejoie and Bertrand Ponchon, Founding Partners of the start-up, “TWIN CORP will be able to take off quickly thanks to a growing group and will benefit from customer and network synergies.”

 

CONTACT SBT

Edouard Blanchard

SBT Group Board Member

e.blanchard@sbt.fr

 

INVESTOR/PRESS CONTACT

Amalia Naveira/Marie-Claude Triquet

ACTUS Lyon

Tel: 00 33 4 72 18 04 93

anaveira@actus.fr/mctriquet@actus.fr

 

About SBT

A Euronext listed company, SBT, Scientific Brain Training, is a group specializing in consulting and development of innovative services that integrate new technologies, cognitive engineering, and neuroscience. Its expertise is organized around 2 activities:

  • The Consulting and Human Resources activity covers the value chain, including strategy consulting, talent detection and development, along with the design of multi-channel training programs (face-to-face and e-learning).
  • The Smart Health activity focuses on health professionals and the general public. It designs, develops, and markets interactive applications and software for a wide range of uses, directed both at target populations (children, adults, seniors) and specific pathologies (dyslexia, attention disorders, Alzheimer’s disease, multiple sclerosis, etc.) or situations (at home, with a practitioner, or in the workplace).

See the press release PDF (in French):  The SBT Group acquires the international coaching platform TWIN CORP

 

/par

Steady growth in 2015

Sales up 15.9%: €10.184 million

Net income +51%: €0.497 million

SBT, Scientific Brain Training, (FR0004175222, MLSBT) is a group specializing in consulting and development of innovative services that integrate new technologies, cognitive engineering, and neuroscience.

In 2015, SBT enjoyed a significant increase in consolidated sales (+15.9%), reaching €10.184 million (or +€1.4 million compared to 2014) under satisfactory profitability conditions with a net profit after tax and before goodwill of €497,000, or 4.9% of sales.

Good organic sales growth, +11,8%, was boosted by sales in the second half of the year provided by the acquisition of the business assets of MOTUS, a health sector company.

Results for the 2015 financial year (January 1 – December 31)

Consolidated sales in €K 2015 2014 Variation
Sales 10,184.9 8,782.2 +1,402.7
EBITDA 847.9 1074,1 -226.2
Net income of integrated companies 497.6 329.2 +168.4

 

On December 31, 2015, the Group had a solid balance sheet structure with shareholder equity amounting to €5.17 million (+€0.2 million), financial debts of €760,000 (+€451,000) and €1.25 million in cash holdings.

 

Consolidation of the Consulting & HR Division

After record growth in 2014, the Consulting & HR Division continued its sales growth, posting an increase of 14% (€8.405 million) with slightly less profitability than in 2014.

There were two major highlights for 2015:

  • A necessary increase in staffing to continue investing in the development of a broader range of innovative services for key accounts
  • A necessary adaptation within the Symetrix Digital Learning subsidiary, both in terms of the offer strategy and the organization of the production and management control processes.

 

Significant turnaround in Health Division results

Following the merger of two entities in the Health division and the acquisition of MOTUS’s business assets in the summer of 2015, the performance of the healthcare business continued the growth pattern begun in 2014. Consolidated sales grew by 37% to reach €1.64 million (compared to €1.19 million in 2014) and the net income of integrated companies rose sharply from €68,000 to €246,000.

This strong growth confirms the importance of the chosen strategy for developing the business.

 

In 2016, the SBT Group intends to pursue its growth strategy while improving its profitability.

 

/par

SBT acquires a stake in Happy Blue Fish (HBF)

SBT (FR0004175222, MLSBT) is a group specializing in consulting and development of innovative services that integrate new technologies, cognitive engineering, and neuroscience.

As part of its open innovation program, SBT announced today that it has taken a minority stake in the Brittany-based company Happy Blue Fish (HBF).

This young, innovative company designs, produces and publishes video games exclusively for tablets and cell phones. Specializing in games for children (edutainment) and the general public, HBF is a “pure player” in this new and highly promising market for the digital distribution of video games (via App Stores:  ).

For SBT’s Chairman Olivier Fronty, and Franck Tarpin-Bernard, the Group’s Managing Director, « this investment shows our desire to develop a network of privileged partners in key thematic areas that we want to support.” The interest is twofold in the case of Happy Blue Fish. First, we wanted to strengthen our expertise in the design and distribution of mobile applications, which have become a crucial means of diffusion for our content. In addition, HBS is developing an innovation program supported by BPI France that aims to improve mobile application user experience, a strategic subject for our business, whether for brain training, e-learning, or coaching.

For Dominique Busso, Happy Blue Fish’s Founder and CEO, and former Technology Director for the game publisher Mindscape, “SBT will allow us to speed up our innovation projects, not only through its financial contribution, but also thanks to the many human, business, and technological synergies between the two companies.”

 

In 2016, HBF generated €286,000 in turnover and €12,000 in net income after taxes.

About SBT

A Euronext listed company, SBT, Scientific Brain Training, is a group specializing in consulting and development of innovative services that integrate new technologies, cognitive engineering, and neuroscience. Its expertise is organized around 2 activities:

  • The Consulting and Human Resources activity covers the value chain, including strategy consulting, talent detection and development, along with the design of multi-channel training programs (face-to-face and e-learning).
  • The Smart Health activity focuses on health professionals and the general public. It designs, develops, and markets interactive applications and software for a wide range of uses, directed both at target populations (children, adults, seniors) and specific pathologies (dyslexia, attention disorders, Alzheimer’s disease, multiple sclerosis, etc.) or situations (at home, with a practitioner, or in the workplace).

See the press release PDF (in French):  SBT strengthens its divisions of expertise by taking a stake in Happy Blue Fish

 

/par

Partnership with Boehringer Ingelheim for a medical trial on schizophrenia

,

Happyneuron to provide a Computerized Cognitive Training program for a large clinical trial by Boehringer Ingelheim investigating combined schizophrenia therapy

 

Happyneuron SAS, a subsidiary of SBT Human(s) Matter Group, announces that it has been chosen by Boehringer Ingelheim, one of the pharmaceutical industry’s top 20 companies, to provide the at-home computerized cognitive training (CCT) for inclusion in an international multicentric clinical trial[1] that investigates the efficacy of a potential new treatment.

 

This trial will compare the effect of BI 425809 to placebo on cognition in patients with schizophrenia on a background of stable antipsychotic treatment and of at-home computerized cognitive training. First patients are planned to be included in April 2019. For the first time, an at-home cognitive training is added to the scientific design in the framework of a large international clinical trial in the CNS field.

 

This trial is critical to the scientific field for several reasons: The results will show if there is an enhanced benefit to combining pharmacotherapy with increased cognitive stimulation through at-home CCT in patients with schizophrenia. Second, the trial will evaluate the impact of BI 425809 with adjunctive CCT on outcomes relating to patients’ daily functioning. Finally, it will demonstrate if at-home CCT can be effectively implemented in a large trial across many centers and several countries. One key strength of this trial is the relatively large sample size which should result in robust data.

 

These combination trials are extremely rare, and this can open a new path for research in many other medical conditions if we can demonstrate the potentiation of drug effect by CCT.

 

According to Franck Tarpin-Bernard, President of Happyneuron, “this new partnership with a top pharmaceutical company is a great acknowledgment of the work we have done in the last twenty years. Happyneuron was a pioneer of cognitive training and our long experience in schizophrenia is thus fully recognized. The at-home version that has been specially developed for Boehringer Ingelheim will aim at helping thousands of patients to benefit from better cognitive remediation. We have been waiting for many years to find a pharmaceutical company that would accept to study how CTT can leverage the effect of drugs and we are very happy that Boehringer Ingelheim launched such a clinical trial.”

 

Happyneuron SAS, is the French leader of Cognitive Stimulation solutions. Pioneer of the field, Happyneuron serves more than 8500 Healthcare professionals mainly in French and English-speaking countries. More than 300.000 patients suffering from various cognitive impairments are using Happyneuron solutions daily. Happyneuron is a subsidiary of SBT, a listed company on Euronext Access market (ISIN FR0004175222 MLSBT). Combining Digital and Cognitive Sciences, SBT Human(s) Matter invents and builds experiences and usages to serve men and women fulfillment. Able to assess and develop individual and collective skills, SBT Human(s) Matter is unique in France and in Europe as a leader of “Brain Tech” applied to professional services and healthcare.

[1] The trial (NCT03859973) aims at recruiting 200 patients with stable schizophrenia in 6 countries and approximately 40 research sites.

/par

Partenariat avec Boehringer Ingelheim pour une étude clinique sur la schizophrénie

Happyneuron va fournir un programme digital de remédiation cognitive dans le cadre d’un essai clinique de grande ampleur conduit par Boehringer Ingelheim investiguant une thérapie combinée pour des patients atteints de schizophrénie

Happyneuron SAS, filiale du groupe SBT Human (s) Matter est fier d’annoncer qu’il a été choisi par Boehringer Ingelheim, l’une des 20 plus grandes entreprises de l’industrie pharmaceutique, pour fournir un programme digital d’entraînement cognitif à domicile (computerized cognitive training / CCT) qui a été inclus dans un essai clinique multicentrique international [1].

Cet essai comparera, dans un contexte de traitement antipsychotique stable et d’un entraînement cognitif digital et à domicile, l’effet du BI 425809 par rapport au placebo. Les premières inclusions ont commencé en avril 2019.

Cet essai est essentiel pour plusieurs raisons. Premièrement, les résultats montreront s’il est plus avantageux d’associer une pharmacothérapie à une stimulation cognitive intensive par le biais de la CCT à domicile chez des patients atteints de schizophrénie. Deuxièmement, l’essai évaluera l’impact du BI 425809 combiné à un CCT complémentaire sur les résultats liés au fonctionnement quotidien des patients. Enfin, cela démontrera si le CCT à domicile peut être efficacement mis en œuvre dans le cadre d’un vaste essai dans de nombreux centres et dans plusieurs pays. L’un des principaux atouts de cet essai réside dans la taille relativement importante de l’échantillon, qui devrait permettre d’obtenir des données fiables.

Ces essais combinés sont extrêmement rares et peuvent ouvrir une nouvelle voie pour la recherche dans de nombreux autres contextes médicaux si nous pouvons démontrer la potentialisation de l’effet médicamenteux par le CCT à domicile.

Pour Franck Tarpin-Bernard, président de Happyneuron, « ce nouveau partenariat avec un grand laboratoire pharmaceutique est une reconnaissance du travail que nous avons accompli au cours des vingt dernières années. Happyneuron a été un pionnier de l’entraînement cognitif et notre longue expérience de la schizophrénie est donc pleinement reconnue. La version à domicile spécialement conçue pour Boehringer Ingelheim aidera, espérons-le, des milliers de patients à bénéficier d’une meilleure remédiation cognitive. Nous cherchions depuis de nombreuses années une entreprise pharmaceutique qui accepterait d’étudier comment le CTT à domicile peut améliorer l’effet des médicaments et nous sommes très heureux que Boehringer Ingelheim ait lancé un tel essai clinique. « 

A propos de Happyneuron SAS

Happyneuron SAS, est le leader français des solutions de stimulation cognitive. Pionnier du secteur, Happyneuron sert plus de 8 500 professionnels de la santé principalement dans les pays francophones et anglophones. Plus de 300 000 patients souffrant de divers troubles cognitifs utilisent quotidiennement les solutions de Happyneuron. Happyneuron est une filiale de SBT, société cotée sur le marché d’Euronext Access (ISIN FR0004175222 MLSBT). Alliant sciences cognitives et technologies du digital, SBT Human(s) Matter invente et fabrique les expériences et les usages de demain au service de l’épanouissement des individus. Capable d’évaluer et de développer les compétences individuelles et collectives, SBT Human (s) Matter est une référence unique en France et en Europe d’activités «Brain Tech» intégrées aux professional services et au secteur de la prévention-santé.

SBT Human(s) Matter est présent dans 4 pays (France, Etats-Unis, Chine, Maroc) et possède 4 bureaux en France (Paris, Lyon, Grenoble et Toulouse). SBT compte 100 collaborateurs.

Pour plus d’informations: https://www.sbt-human.com

[1] L’essai (NCT03859973) vise à recruter 200 patients stabilisés atteints de schizophrénie dans 6 pays et environ 40 sites de recherche.

/par